Amgen/UCB's Phase III Success May Not Be Enough To Top Osteoporosis Rivals
Romosozumab shows ability to reduce risk of spinal fractures, but misses a secondary endpoint on nonvertebral fracture risk reduction.
Romosozumab shows ability to reduce risk of spinal fractures, but misses a secondary endpoint on nonvertebral fracture risk reduction.